Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024
Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT –
— 美国东部时间下午 5:00 /太平洋时间下午 2:00 将进行电话会议和网络直播 —
ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 16, 2024-- Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2024 financial results will be released on Tuesday, April 30, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website.
加利福尼亚州阿拉米达--(美国商业资讯)--2024年4月16日-- Exelixis, Inc. 纳斯达克股票代码：EXEL）今天宣布，其2024年第一季度财务业绩将在市场收盘后于2024年4月30日星期二公布。美国东部时间下午 5:00 /太平洋时间下午 2:00，Exelixis管理层将主持电话会议和网络直播，讨论结果并提供一般业务最新情况。该公司的网站可通过互联网访问该活动。
To access the conference call, please register using this link. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.exelixis.com and proceed to the Event Calendar page under the Investors & News heading. A webcast replay of the conference call will also be archived on www.exelixis.com for one year.
要参加电话会议，请使用此处进行注册 链接。注册后，将提供拨入号码和唯一的 PIN 码以加入通话。要访问网络直播链接，请登录 www.exelixis.com 然后前往 “投资者与新闻” 标题下的 “活动日历” 页面。电话会议的网络直播重播也将存档于 www.exelixis.com 为期一年。
About Exelixis
关于 Exelixis
Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit www.exelixis.com, follow @ExelixisInc on X (Twitter), like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn.
Exelixis是一家雄心勃勃的全球肿瘤公司，致力于在癌症治疗的最前沿创新下一代药物和方案。在卓越的药物发现和开发能力的推动下，我们正在迅速发展我们的产品组合，通过我们具有临床差异化的小分子、抗体药物偶联物和其他生物疗法产品线，靶向越来越多的肿瘤类型和适应症。这种全面的方法利用数十年来对我们的科学和合作伙伴关系的强大投资来推进我们的研究计划，扩大我们的旗舰商业产品CABOMETYX的影响力 （卡博赞替尼）。Exelixis的驱动力是大胆的科学追求，即创造变革性的治疗方法，让更多的患者对未来充满希望。有关该公司及其帮助癌症患者恢复健康、延长寿命的使命的信息，请访问 www.exelixis.com，关注 @ExelixisInc 在 X（Twitter）上，比如 Exelixis, Inc. 在 Facebook 上关注吧 Exelixis 在领英上。
Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks.
Exelixis、Exelixis 徽标和 CABOMETYX 是美国的注册商标。
View source version on businesswire.com: https://www.businesswire.com/news/home/20240416694147/en/
Investors Contact:
Varant Shirvanian
Director, Investor Relations
Exelixis, Inc.
650-837-7917
vshirvanian@exelixis.com
投资者联系方式：
Varant Shirvanian
投资者关系董事
Exelixis, Inc.
650-837-7917
vshirvanian@exelixis.com
Media Contact:
Hal Mackins
For Exelixis, Inc.
415-994-0040
hal@torchcommunications.com
媒体联系人：
哈尔·麦金斯
适用于 Exelixis, Inc.
415-994-0040
hal@torchcommunications.com
Source: Exelixis, Inc.
来源：Exelixis, Inc.